Core Insights - DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting from November 6 to 10 in Orlando, Florida [1] - The company will host a Product Theater discussing the benefits of early intervention in food allergy management [2][3] - A planned Phase 2 clinical study will assess the efficacy and safety of the VIASKIN® Peanut patch for peanut-allergic infants aged 6 to 12 months [2][4] Product Theater Details - Dr. Gideon Lack will lead discussions on proactive food allergy management and the potential of the VIASKIN® Peanut patch [3] - The study aims to determine if earlier intervention can facilitate ad lib peanut consumption in young children [3] - Dr. Matthew Greenhawt will present end-of-study results from the EPITOPE study during the meeting [3][8] Company Commitment - DBV Technologies emphasizes its commitment to the younger patient population in the food allergy community [4] - The company anticipates a potential BLA filing for the VIASKIN® Peanut patch for toddlers aged 1 to 3 years in the second half of next year [4] - DBV is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology [9] Event Participation - DBV will exhibit at booth 711 and sponsor the 34th Annual FIT Bowl™, a competition testing knowledge in allergy, asthma, and immunology [6] - The competition is scheduled for November 8, 2025 [6] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [10] - The company is dedicated to transforming the care of individuals with food allergies through innovative therapies [9]